Table 2. Multivariate analysis of risk factors of immune-related adverse events (irAEs). Combination therapy was an independent risk factor for pyrexia and neutropenia.
| Variable | Pyrexia | Neutropenia | Pneumonitis | |||||
|---|---|---|---|---|---|---|---|---|
| Adjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value | |||
| Combination therapy | 2.12 (1.43–3.16) | <0.001 | 1.89 (1.39–2.56) | <0.001 | 0.76 (0.46–1.24) | 0.270 | ||
| Comorbidity | 0.48 (0.32–0.71) | <0.001 | 0.79 (0.67–1.43) | 0.913 | 1.04 (0.80–1.34) | 0.789 | ||
| Disease progression | 1.32 (1.12–1.55) | 0.001 | 0.53 (0.38–0.74) | <0.001 | 0.73 (0.61–0.86) | <0.001 | ||
| Stage IV | 0.91 (0.68–1.23) | 0.534 | 1.22 (0.92–1.64) | 0.173 | 0.72 (0.53–0.96) | 0.025 | ||
| Chemotherapy | 0.74 (0.59–0.92) | 0.007 | 9.09 (11.37–7.27) | <0.001 | 0.77 (0.63–0.93) | 0.007 | ||
CI, confidence interval.